Completed PHASE3 INTERVENTIONAL 2-arm NCT02012062

Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC

Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy With Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).

Sponsor: Fudan University

Conditions Nasopharyngeal Carcinoma

Interventions Concurrent chemotherapy with cisplatin during radiotherapy Concurrent nimotuzumab during radiotherapy Radical radiotherapy TPF neoadjuvant chemotherapy

Updated 7 times since 2017 Last updated: Apr 8, 2019 Started: Jul 31, 2012 Primary completion: Mar 31, 2016 Completion: Aug 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Nasopharyngeal Carcinoma, this trial is completed. The trial is conducted by Fudan University and has accumulated 7 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
May 2019 — Jan 2021 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jul 2018 — May 2019 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University
Fujian Province Tumor Hospital
The First Affiliated Hospital of Xiamen University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China